Evidence map›Paper›PMID 12634380›Full record

ArticleJournal of virology2003

Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein.

X Zhan, K S Slobod, S Surman, S A Brown, T D Lockey, C Coleclough, P C Doherty, J L Hurwitz

2 registry-linked trialsOpen access · greenAbstract read
In one paragraph

Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00051922 phase1completednot on this map

Evaluation of the Safety of a Polyvalent Vaccinia Virus HIV-1 Envelope Recombinant Vaccine (PolyEnv1) in Healthy Adults

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran1997 to 2009Enrolled24ConditionsHIV InfectionsArmsPolyEnv1
NCT00076947 phase1completednot on this map

Evaluation of Tolerability and Safety of a Recombinant Purified HIV Envelope Vaccine

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2003Enrolled10ConditionsHIV InfectionsArmsEnvPro
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

X ZhanDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105-2794, USA.
K S Slobod
S Surman
S A Brown
T D Lockey
C Coleclough
P C Doherty
J L Hurwitz
Office of Infectious Diseases · USUniversity of Tennessee Health Science Center · USSt. Jude Children's Research Hospital · US

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
SINGLE CELL ANALYSIS OF A MULTI-TIER AIDS VACCINEP01AI045142 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HURWITZ, JULIA L · 1999 to 2004
$7.0M
NCI NIH HHS P30 CA021765NCI NIH HHS P30-CA21765NIAID NIH HHS P01 AI045142NIAID NIH HHS P01-AI45142
6 · The paper itself

Abstract

Single-envelope human immunodeficiency virus (HIV) vaccines have been studied for more than a decade, with some successes in homologous challenge experiments in nonhuman primates but with no clear successes in clinical trials. To gain insight into the breadth of the immunity elicited by such vaccines, we have dissected the T-helper cell response of C57BL/6 mice to an individual, molecularly cloned envelope protein. Here, we report that T-helper cells responsive to HIV type 1 1035 envelope are very highly restricted in C57BL/6 animals: seven different hybridomas recovered from five separate mice recognized the same peptide, PKVSFEPIPIHYCAP, located in the C2 region of gp120. Three of these hybridomas were tested on a natural variant of the peptide but failed to respond. A more extensive analysis of whole splenic populations from other C57BL/6 mice immunized with the 1035 envelope reproducibly confirmed that the gp120-specific T-helper response was almost exclusively focused on a single epitope. We conclude that single-envelope vaccines may frequently fail to provoke an immune response sufficiently diverse to recognize variant sequences among circulating HIV. The results encourage the inclusion of more than one envelope in future vaccines to enhance the potential diversity and respective surveillance capacities of responding T-helper cell populations.

Indexed as

AIDS VaccinesAmino Acid SequenceAnimalsAntibody Specificityenv Gene Products, Human Immunodeficiency VirusEpitopesFemaleGene Products, envHIV-1HIV AntibodiesHIV Envelope Protein gp120HumansHybridomasMiceMice, Inbred C57BLMolecular Sequence DataAIDS Vaccinesenv Gene Products, Human Immunodeficiency VirusEpitopesGene Products, envgp140 envelope protein, Human immunodeficiency virus 1HIV AntibodiesHIV Envelope Protein gp120Peptide Fragments

Identifiers

PMID12634380
PMCPMC150625
OpenAlexW2156038330

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.